Sedative clearance during extracorporeal membrane oxygenation

The effects of polyvinyl chloride (PVC) tubing and membrane oxygenator (MO) on the concentrations of lorazepam and morphine in the neonatal extracorporeal membrane oxygenation (ECMO) circuit were evaluated using an in vitro model that included a closed ECMO circuit with a MO, heat exchanger, bladder and PVC tubing. The circuit was primed with blood, electrolytes, albumin and heparin and maintained at physiologic pH and temperature throughout by frequent measurement of blood gas pH and a temperature probe. Lorazepam and morphine were each studied separately in three separate, but identical circuits for 6 h on the day of circuit prime (new circuit) and then again for 6 h at 24 h (old circuit). Each circuit (new and old) was spiked once with lorazepam to a final concentration of 250 ng/mL or with morphine to a final concentration of 70 ng/mL in the circuit. Serial samples were drawn at baseline and every 30/60 min for 6 h at the site of injection and pre- and post-MO for each circuit. Lorazepam and morphine concentrations were analysed using gas chromatography with electron capture and gas chromatography with mass spectrometry, respectively. The concentrations of morphine and lorazepam at various sample sites and time points were expressed as a percentage of the original concentration. This single-dose study shows that up to 50% of a dose of lorazepam and 40% of a dose of morphine may be extracted by PVC and MO during bypass, depending on the age of the circuit. As the circuits become older, this amount could increase. These data may explain, in part, the higher doses of lorazepam and morphine required to sedate patients during ECMO.

[1]  G. Koren,et al.  Sequestration of fentanyl by the cardiopulmonary bypass (CPBP) , 2004, European Journal of Clinical Pharmacology.

[2]  M. Buck Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation , 2003, Clinical pharmacokinetics.

[3]  H. Mulla,et al.  Effects of neonatal extracorporeal membrane oxygenation circuits on drug disposition , 2000 .

[4]  H. Mulla,et al.  In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation , 2000, Perfusion.

[5]  G. Trittenwein,et al.  Issues of pharmacology in pediatric cardiac extracorporeal membrane oxygenation with special reference to analgesia and sedation. , 1999, Artificial organs.

[6]  M. Buck,et al.  Phenobarbital Dosing and Pharmacokinetics in a Neonate Receiving Extracorporeal Membrane Oxygenation , 1999, The Annals of pharmacotherapy.

[7]  M. Buck Vancomycin Pharmacokinetics in Neonates Receiving Extracorporeal Membrane Oxygenation , 1998, Pharmacotherapy.

[8]  S. Bratton,et al.  Morphine pharmacokinetics during continuous infusion of morphine sulfate for infants receiving extracorporeal membrane oxygenation. , 1997, Critical care medicine.

[9]  J. Dipiro,et al.  Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation , 1996, Antimicrobial agents and chemotherapy.

[10]  J. Fackler,et al.  The impact of extracorporeal membrane oxygenation on survival in pediatric patients with acute respiratory failure. Pediatric Critical Care Study Group. , 1996, Critical care medicine.

[11]  B. Peterson,et al.  New concepts in the treatment of children with acute respiratory distress syndrome. , 1995, The Journal of pediatrics.

[12]  G. Koren,et al.  Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants , 1994, Critical care medicine.

[13]  M. Klein,et al.  Extracorporeal membrane oxygenation. , 1994, Pediatric clinics of North America.

[14]  P. Pelosi,et al.  Role of extracorporeal circulation in adult respiratory distress syndrome management. , 1993, New horizons.

[15]  G. Koren,et al.  Preliminary Studies of the Effects of Extracorporeal Membrane Oxygenator on the Disposition of Common Pediatric Drugs , 1993, Therapeutic drug monitoring.

[16]  H. Mangurten,et al.  Pharmacokinetics of lorazepam in critically ill neonates with seizures. , 1992, The Journal of pediatrics.

[17]  R. Schumacher,et al.  Gentamicin Pharmacokinetics in Term Neonates Receiving Extracorporeal Membrane Oxygenation , 1992, Pharmacotherapy.

[18]  P. Munzenberger,et al.  Pharmacokinetics of Gentamicin in Neonatal Patients Supported with Extracorporeal Membrane Oxygenation , 1991, ASAIO transactions.

[19]  R. Steinhorn,et al.  Inactivation of heparin during extracorporeal circulation in infants. , 1991, Clinical pharmacology and therapeutics.

[20]  T F Blaschke,et al.  Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation , 1990, The Pediatric infectious disease journal.

[21]  J. Dipiro,et al.  Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation , 1989, Antimicrobial Agents and Chemotherapy.

[22]  Lawrence A. Trissel,et al.  Handbook on Injectable Drugs , 1983 .